Short Interest in ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Declines By 54.6%

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) was the recipient of a significant decline in short interest in the month of February. As of February 28th, there was short interest totalling 44,400 shares, a decline of 54.6% from the February 13th total of 97,800 shares. Based on an average daily volume of 816,400 shares, the days-to-cover ratio is presently 0.1 days. Approximately 1.8% of the shares of the company are short sold.

ZyVersa Therapeutics Price Performance

Shares of ZyVersa Therapeutics stock opened at $0.80 on Friday. The firm has a fifty day moving average price of $1.24 and a 200 day moving average price of $1.62. ZyVersa Therapeutics has a 1 year low of $0.80 and a 1 year high of $10.20.

Institutional Trading of ZyVersa Therapeutics

A hedge fund recently bought a new stake in ZyVersa Therapeutics stock. Virtu Financial LLC acquired a new position in shares of ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 25,259 shares of the company’s stock, valued at approximately $27,000. Virtu Financial LLC owned 1.08% of ZyVersa Therapeutics at the end of the most recent reporting period. 3.91% of the stock is currently owned by institutional investors.

ZyVersa Therapeutics Company Profile

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.